SCHEMBL12458587

COC1[C@@H](OC)[C@H](O[C@H]2[C@H](OC)[C@@H](OS(=O)(=O)O)[C@@H](C)O[C@@H]2COS(=O)(=O)O)O[C@@H](C(=O)O)[C@H]1O[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](OC)[C@H](OC)[C@H]3OC)[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)O)[C@H]1OS(=O)(=O)O

nearest known ligand 0.75

Predicted protein targets (top 6)

	gene	UniProt	supporting neighbours	confidence
▸	SERPINC1	P01008	3/20	0.75

▸	FGF1	P05230	4/20	0.52

▸	F10	P00742	5/20	0.52

▸	F2	P00734	1/20	0.51

▸	FGF2	P09038	1/20	0.49

▸	HPSE	Q9Y251	8/20	0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29407493	0.93	SERPINC1 (0.85)	SERPINC1FGF1F10F2FGF2
Idraparinux SCHEMBL427808	0.93	SERPINC1 (0.85)	SERPINC1FGF1F10F2FGF2
Idraparinux SCHEMBL29382311	0.93	SERPINC1 (0.85)	SERPINC1FGF1F10F2FGF2
SCHEMBL4732494	0.93	SERPINC1 (0.66)	SERPINC1FGF1F10F2FGF2
SCHEMBL13551204	0.93	SERPINC1 (0.66)	SERPINC1FGF1F10F2FGF2
SCHEMBL6973207	0.92	SERPINC1 (0.64)	SERPINC1FGF1F10F2FGF2
SCHEMBL13551196	0.90	SERPINC1 (0.63)	SERPINC1FGF1F10F2FGF2
SCHEMBL12729453	0.87	SERPINC1 (0.74)	SERPINC1FGF1F10F2FGF2
SCHEMBL15896273	0.82	SERPINC1 (0.69)	SERPINC1FGF1F10F2FGF2
SCHEMBL12799309	0.81	SERPINC1 (0.68)	SERPINC1FGF1F10F2FGF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20120238512-A1	ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE	MSD OSS B.V. (NL)	2012-09-20	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20120238512-A1	ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE	BRS3, SERPINC1, TBXA2R	SERPINC1 2/4885FGF1 4276/4885F10 313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.